论文部分内容阅读
目的探讨孕晚期注射乙肝免疫球蛋白(HBIG)对阻断HBV母婴传播有无作用。方法选取538例孕晚期注射HBIG和817例未注射HBIG的孕妇及其婴儿,比较两组的宫内感染率。结果 (1)HBIG组和对照组的宫内感染率分别为2.2%和1.1%,两组相比差异无统计学意义(P>0.05);(2)当母亲同为HBeAg阳性时,两组的宫内感染率相比,差异无统计学意义(4.14%vs.4.92%,P>0.05);当母亲同为HBV DNA阳性时,两组的宫内感染率相比,差异仍无统计学意义(3.14%vs.3.10%,P>0.05);(3)进一步将孕妇血清HBV DNA按浓度高低进行分层分析,当HBV DNA浓度相同时,两组的宫内感染率相比,差异无统计学意义(P>0.05)。结论孕期注射HBIG对阻断HBV母婴传播无明显作用,不推荐孕期使用HBIG。
Objective To investigate the effect of injecting HBIG in the third trimester of pregnancy on the blocking of mother-to-child transmission of HBV. Methods 538 pregnant women and their infants who were injected with HBIG and 817 without HBIG were enrolled in the third trimester of pregnancy. The intrauterine infection rate was compared between the two groups. Results (1) The intrauterine infection rates of HBIG group and control group were 2.2% and 1.1%, respectively. There was no significant difference between the two groups (P> 0.05). (2) When the mothers were HBeAg positive, (4.14% vs 4.92%, P> 0.05). However, there was no statistical difference in the intrauterine infection rates between the two groups when the mother was HBV DNA positive (3.14% vs.3.10%, P> 0.05). (3) Serum HBV DNA levels in pregnant women were further stratified by concentration. When the HBV DNA concentrations were the same, the intrauterine infection rates of the two groups were no difference Statistical significance (P> 0.05). Conclusion HBIG injection during pregnancy has no obvious effect on blocking the transmission of HBV from mother to mother, and it is not recommended to use HBIG during pregnancy.